U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H17NO3
Molecular Weight 223.2683
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NICOBOXIL

SMILES

CCCCOCCOC(=O)C1=CN=CC=C1

InChI

InChIKey=IZJRISIINLJVBU-UHFFFAOYSA-N
InChI=1S/C12H17NO3/c1-2-3-7-15-8-9-16-12(14)11-5-4-6-13-10-11/h4-6,10H,2-3,7-9H2,1H3

HIDE SMILES / InChI
Molecular Formula C12H17NO3
Molecular Weight 223.2683
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: for description additional reference was used http://onlinelibrary.wiley.com/doi/10.1002/ejp.719/full

Nicoboxil is a nicotinate used in topical preparations as a rubefacient which has vasodilating properties mediated by prostaglandin. Nicoboxil is a component of finalgon® (nonivamid and nicoboxil), a topical cream for joint and muscle pains. The hyperaemic effect of Nicoboxil has an earlier onset and it is more intense than the nonivamide hyperaemic effect.

Originator

Boehringer Ingelheim
131
Curator's Comment: Topical nicoboxil/nonivamide ointment (Finalgon®, Boehringer Ingelheim, Germany) has been used since the 1950s to treat discomfort of the musculoskeletal system (Ward, 1955; Chitil and Ortner, 1959).

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Activator
1430
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Finalgon

Approved Use

Nicobaxol as a component of Finalgon is used for the temporary relief of the pain of rheumatism, arthritis, lumbago, muscular aches, sprains and strains, sporting injuries and other conditions where local warmth is beneficial.

Launch Date

1994
PubMed

PubMed

TitleDatePubMed
Improved dorsal random-pattern skin flap survival in rats with a topically applied combination of nonivamide and nicoboxil.
2003 Mar
A comparison of pretreatment with a topical combination of nonivamide and nicoboxil and surgical delay in a random pattern skin flap model.
2009 Jul
Evaluation of changes in the haemoglobin of skin and muscle tissue of the calf, as induced by topical application of a nonivamide/nicoboxil cream.
2014 Feb
Efficacy and safety of nicoboxil/nonivamide ointment for the treatment of acute pain in the low back - A randomized, controlled trial.
2016 Feb
Topical application of cream containing nonivamide and nicoboxil does not enhance the performance of experienced cyclists during a 4-km time-trial.
2016 May

Sample Use Guides

In Vivo Use Guide
Ointment; Topical; Nonivamide 0.4% mg; Nicoboxil 2.5%
Route of Administration: Topical
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:10:48 GMT 2023
Edited
by admin
on Fri Dec 15 15:10:48 GMT 2023
Record UNII
GSD5B9US0W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NICOBOXIL
INN   MART.   WHO-DD  
INN  
Official Name English
NICOBOXIL [MART.]
Common Name English
nicoboxil [INN]
Common Name English
BETA-BUTOXYETHYL NICOTINATE [JAN]
Common Name English
BUTOXYETHYL NICOTINATE
INCI  
INCI  
Official Name English
BETA-BUTOXYETHYL NICOTINATE
JAN  
Systematic Name English
2-BUTOXYETHYL NICOTINATE
Systematic Name English
Nicoboxil [WHO-DD]
Common Name English
BUTOXYETHYL NICOTINATE [INCI]
Common Name English
.BETA.-BUTOXYETHYL NICOTINATE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C241
Created by admin on Fri Dec 15 15:10:48 GMT 2023 , Edited by admin on Fri Dec 15 15:10:48 GMT 2023
Code System Code Type Description
FDA UNII
GSD5B9US0W
Created by admin on Fri Dec 15 15:10:48 GMT 2023 , Edited by admin on Fri Dec 15 15:10:48 GMT 2023
PRIMARY
RXCUI
235788
Created by admin on Fri Dec 15 15:10:48 GMT 2023 , Edited by admin on Fri Dec 15 15:10:48 GMT 2023
PRIMARY RxNorm
EPA CompTox
DTXSID4057635
Created by admin on Fri Dec 15 15:10:48 GMT 2023 , Edited by admin on Fri Dec 15 15:10:48 GMT 2023
PRIMARY
MESH
C473307
Created by admin on Fri Dec 15 15:10:48 GMT 2023 , Edited by admin on Fri Dec 15 15:10:48 GMT 2023
PRIMARY
ChEMBL
CHEMBL2105161
Created by admin on Fri Dec 15 15:10:48 GMT 2023 , Edited by admin on Fri Dec 15 15:10:48 GMT 2023
PRIMARY
INN
4757
Created by admin on Fri Dec 15 15:10:48 GMT 2023 , Edited by admin on Fri Dec 15 15:10:48 GMT 2023
PRIMARY
EVMPD
SUB09231MIG
Created by admin on Fri Dec 15 15:10:48 GMT 2023 , Edited by admin on Fri Dec 15 15:10:48 GMT 2023
PRIMARY
ECHA (EC/EINECS)
237-684-7
Created by admin on Fri Dec 15 15:10:48 GMT 2023 , Edited by admin on Fri Dec 15 15:10:48 GMT 2023
PRIMARY
PUBCHEM
14866
Created by admin on Fri Dec 15 15:10:48 GMT 2023 , Edited by admin on Fri Dec 15 15:10:48 GMT 2023
PRIMARY
DRUG BANK
DB12911
Created by admin on Fri Dec 15 15:10:48 GMT 2023 , Edited by admin on Fri Dec 15 15:10:48 GMT 2023
PRIMARY
NCI_THESAURUS
C84007
Created by admin on Fri Dec 15 15:10:48 GMT 2023 , Edited by admin on Fri Dec 15 15:10:48 GMT 2023
PRIMARY
CAS
13912-80-6
Created by admin on Fri Dec 15 15:10:48 GMT 2023 , Edited by admin on Fri Dec 15 15:10:48 GMT 2023
PRIMARY
SMS_ID
100000084188
Created by admin on Fri Dec 15 15:10:48 GMT 2023 , Edited by admin on Fri Dec 15 15:10:48 GMT 2023
PRIMARY
Related Record Type Details
Structure of NICOBOXIL
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966